'Methods For Predicting Er-Mediated Dna Damage' in Patent Application Approval Process (USPTO 20210109085)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily- A patent application by the inventors Jerry, D. Joseph (Boston, MA); Majhi, Prabin Kumar Dhangada (Boston, MA); Sharma, Aman (Boston, MA); Dunphy, Karen A. (Boston, US), filed on October 12, 2020, was made available online on April 15, 2021, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to University of Massachusetts (Boston, Massachusetts, United States). The following quote was obtained by the news editors from the background information supplied by the inventors: "Endocrine-disrupting chemicals (EDCs) alter the endocrine system by binding directly to the receptors and modulating downstream signaling pathways. Xenoestrogens are structurally diverse EDCs which affect estrogen receptor (ER) signaling pathways. BP3 (Oxybenzone, or 2-Hydroxy-4-methoxybenzophenone, CAS No. 131-57-7) is a UV-filter used in personal care products, such as sunscreens, cosmetics and lotions, with concentrations up to 0.148% and a maximum allowed concentration of 6% by Food and Drug Administration (FDA) and European commission.